Cellectar to Present at BIO CEO & Investor Digital Conference
Cellectar Biosciences (NASDAQ: CLRB), a biopharmaceutical firm focused on cancer treatment, announced that its CEO, James Caruso, will present a company overview at the virtual 2021 BIO CEO & Investor Digital Conference from February 16-18, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cellectar Biosciences (NASDAQ: CLRB), a biopharmaceutical firm focused on cancer treatment, announced that its CEO, James Caruso, will present a company overview at the virtual 2021 BIO CEO & Investor Digital Conference from February 16-18, 2021. The presentation will be available for on-demand viewing starting February 12, 2021, at 12:00 PM ET. Cellectar's proprietary Phospholipid Drug Conjugate™ (PDC) platform aims to improve cancer therapies, with CLR 131 currently in clinical studies targeting hematologic malignancies. Replays will be accessible on the company’s website.
Details
News Market Reaction – CLRB
The recorded move for CLRB in the trading session of this news was -1.71%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FLORHAM PARK, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and CEO will present a company overview at the virtual 2021 BIO CEO & Investor Digital Conference to be held from February 16-18, 2021.
The presentation will be available to registered conference attendees for on-demand viewing beginning February 12, 2021 at 12:00 PM ET via the virtual conference link.
Replays of the presentation will be available on the Investors section of the Company’s website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.
The company’s product pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells unlike many traditional on-market treatment options. CLR 131, is currently in a clinical study for hematologic malignancies and a pediatric safety study, one preclinical PDC chemotherapeutic program (CLR 1900) and multiple partnered PDC assets.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Contacts
Investors:
Monique Kosse
Managing Director
LifeSci Advisors, LLC
212-915-3820
monique@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.